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Sustained release systems for therapeutic proteins have been widely studied targeting to improve the action 
of these drugs. Molecular entrapping of proteins is particularly challenging due to their conformational 
instability. We have developed a micro-structured poly-epsilon-caprolactone (PCL) particle system loaded 
with human insulin using a simple double-emulsion w/o/w method followed by solvent evaporation 
method. This formulation is comprised by spheric-shaped microparticles with average size of 10 
micrometers. In vitro release showed a biphasic behavior such as a rapid release with about 50% of 
drug delivered within 2 hours and a sustained phase for up to 48 h. The subcutaneous administration of 
microencapsulated insulin showed a biphasic effect on glycemia in streptozotocin-induced diabetic mice, 
compatible with short and intermediate-acting behaviors, with first transition peak at about 2 h and the 
second phase exerting effect for up to 48h after s.c. administration. This study reveals that a simplified 
double-emulsion system results in biocompatible human-insulin-loaded PCL microparticles that might 
be used for further development of optimized sustained release formulations of insulin to be used in the 
restoration of hormonal levels.
Uniterms: Human insulin/study. Microparticles. Poly-ε-caprolactone. Therapeutic proteins/study/action. 
Proteins/molecular entrapping. 
INTRODUCTION
The World Health Organization (WHO) estimates 
that more than 180 million people worldwide are diabetic 
and this health problem is responsible for 5% of all deaths 
each year (Wild et al., 2004; Roglic et al., 2005). The 
Diabetes Mellitus (DM) is a group of chronic diseases 
which occur when pancreas does not produce enough 
insulin or there is a resistance to this hormone, and in 
some cases are observed production and action of insulin 
deficient condition increasing blood sugar level and risk 
of microvascular damage (retinopathy, nephropathy and 
neuropathy) (American Diabetes Association, 2013; 
WHO, 2008).
Insulin is a polypeptide hormone synthesized in the 
β-cells of Langerhans islets in the pancreas. This hormone 
is composed of two chains linked by disulfide bonds, 
chain A with 21 amino acids and chain B with 30 amino 
acids. Hormone replacement therapy using exogenous 
insulin is necessary for patients with DM, especially for 
patients with Type 1 DM. However, a perfect glycemic 
control is still a difficult task despite the number of insulin 
formulations in market with different pharmacokinetics 
characteristics (Veiseh et al., 2015). 
Therefore, the developments of pharmaceutical 
compositions, which reduce the number of insulin 
shots, are needed for both better glycemic control and 
for improving patient’s quality of life. There are many 
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approaches for sustained release development, but not 
all methods are applicable to biopharmaceuticals due 
to its high lability. The most common methods used 
in pharmaceutical biotechnology are: nano and micro-
encapsulation, using solid matrixes as PLGA, PLA and 
PCL; liposomes,, which uses liquid matrixes such as 
phosphatidylcholine; derivatization with polymers, such 
as polyethylene glycol; the use of biocompatible gels, 
such as Pluronic F27; or the combination of two or more 
of these techniques (Calceti et al., 2004; Almeida, Souto, 
2007; Liu et al., 2007a; Liu et al., 2007b; Huynh et al., 
2009; Rastogi, Anand, Koul, 2009).
Several approaches have been proposed to make an 
insulin sustained release system but so far no medicine 
containing micro or nanoencapsuladed insulin has 
been available commercially. In our work, we ought 
to develop a system containing insulin confined into 
polymeric microparticles, which could be used for the 
sustained release of insulin in vivo. In this study, the 
PCL was the polymer of choice because it is of low-
cost, biocompatible, biodegradable and it has been using 
in various formulations (Benoit, Baras, Gillard, 1999; 
Lamprecht et al., 1999; Sinha et al., 2004; Hasan et al., 
2007; Wang et al., 2007). We report here a simple method 
based on double emulsification followed by simple 
vacuum solvent extraction for the production of PCL 
microparticles comprising bioactive insulin.
MATERIAL AND METHODS
Chemicals
Poly-ε-caprolactone (MW 65,000 Da), poly (vinyl 
alcohol) (87-89% hydrolyzed, average MW 31,000-
50,000Da) and streptozotocin (STZ) were obtained from 
Sigma-Aldrich (St. Louis, USA). Biosynthetic human 
insulin Humulin-R ® (recombinant human insulin, 
metacresol, gycerol and water for injection) was obtained 
from local drugstore and stored as directed until use. Type 
I water was used throughout. Other reagents were from 
analytical grade.
Preparation of insulin microparticles
PCL microparticles were prepared by a modified 
double-emulsion (water-in-oil-in-water) solvent 
evaporation/extraction technique (Benoit, Baras, Gillard, 
1999; Damgé et al., 2009). Briefly, 400 mL regular-acting 
human insulin formulation (Humulin R®) and 100 mL of 
5 % PVA aqueous solution was emulsified in a mixed 
organic solution (5 mL of dichloromethane) containing 
PCL (100 mg) by an Ultraturrax® at 10,000 rpm for 1 
min. Thereafter, the primary emulsion was poured into 25 
mL of the 1.5 % PVA aqueous solution and homogenized 
with magnetic stirrer for 10 minutes. The resulting 
emulsion was stirred with a magnetic stirrer in low speed 
and the dichloromethane was purged out by evaporation 
under reduced pressure. The particles were washed out 
by centrifuging for 15 min at 14.000 x g at 4 oC and 
resuspending the particles in 1.5% PVA aqueous solution 
for three times. 
Particle size distribution and morphology
Particle size distribution (mean diameter and 
polydispersity index) of microparticles was determined 
at 25oC by dynamic laser light scattering (Shimadzu 
SALD-2201, Shimadzu, Japan) over the range of 0.005 
to 1,000  mm, in a 1.0 cm quartz cell after proper dilution 
in water. Particle distribution and morphology were 
also evaluated by conventional optical microscopy with 
particles dispersed in water over siliconized glass slide. 
Several viewing fields were registered and particle size 
measurement was performed using ImageJ software 
(version 1.42, National Institutes of Health, USA), 
computed from a set comprising a total of 10,000 
particles randomly selected. Results are representative 
of measurements performed with three microparticles 
preparations (n=3), to confirm mean diameter obtained 
by DLS (data not show). 
Morphological analysis by scanning electron 
microscopy (SEM)
The morphological analysis of the resulting 
microparticles was performed using Scanning Electron 
Microscopy (SEM). In brief, a suspension of the 
microparticles was dispersed onto a glass slide and 
plunge frozen in liquid nitrogen and freeze-dried. Dried 
samples were then coated with 10 nm gold layer at room 
temperature and observed in a JEOL6340 Field Emission 
SEM operating at 5.0 kV.
Insulin encapsulation efficiency and yield
The total amount of insulin entrapped within PCL 
microparticles was accessed by measuring the amount 
of nonentrapped protein in the external aqueous solution 
recovered after centrifugation and washing of the 
microparticles. Protein loading efficiency was expressed 
as the percentage of insulin entrapped with respect to the 
theoretical value (Equation 1). The yield was calculated 
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using the particles after washing and lyophilization. The 
value was the percentage of mass recovered as follow 
(Equation 2). Protein was quantified with the Bradford 
method (Bradford, 1976), using insulin for standard 
curve. Insulin for the standard curve was quantified by 
absorbance measurements at 280 nm (Gill, Von Hippel, 
1989).
 Eq. 1
 Eq. 2
In vitro kinetic release assays
The washed microparticles were dispersed in 
20 mL of PBS pH 7.4 and 0.02% NaN3, distributed 
in centrifugal microtubes containing 1.0 mL of the 
microparticles suspension each and incubated statically at 
37 °C (Guerreiro et al., 2012). This assay was performed 
in sink conditions with the theoretical maximum insulin 
concentration below 0.05 mg/mL. At varying time 
intervals, samples were centrifuged for 30 minutes at 
20,000 g at 4 oC, and the supernatant were assayed for total 
protein released using the Comassie colorimetric method 
(Bradford, 1976).
Pharmacological evaluation in vivo
Pharmacological evaluation of the hypoglycemic 
effect of insulin was performed as previously reported 
(Finotelli et al., 2010) with Swiss male mice (8 weeks; 
27 g ± 1 g), housed in a temperature-controlled room 
with a 12 h light-dark cycle and given free access to 
water and normal chows. Type 1 diabetes was induced 
by one intraperitoneal (ip.) injection of STZ (200 mg/
kg) dissolved in fresh citrate buffer (100 mM, pH 4.5). 
After STZ administration (5 days), blood was drawn 
from mice by tail snip and glucose levels were measured 
using a glucometer (Accu-Chek® Active - Roche). After 
STZ treatment, animals, which show more than 300 mg/
dL, were considered diabetics. Mice were separated in 
three groups: i) control: receiving placebo MP (n= 3); ii) 
receiving soluble regular human insulin (n=5; 5 U/kg); 
and iii) test: receiving insulin-loaded microparticles (n=5; 
10 U/kg). Food was suspended 4 h before the experiments, 
and all mice were fasted throughout the experiments and 
kept at 22±2 oC. Mice were administrated by subcutaneous 
route (s.c.) using a standard 29 gauge needle (BDTM). The 
glycemia was monitored following the recommendations 
of the Mouse Metabolic Phenotyping Center (MMPC) 
Consortium from the National Institutes of Health (NIH) 
(Ayala et al., 2010) by using whole blood from the tail tip of 
conscious, unrestrained mice using pre-calibrated point-of-
care glucometers (Accu-Chek® Active, Roche Diagnostics, 
Germany; Serial No GN08146937) before injection and at 
repeated intervals after administration. The pharmacological 
evaluation over a prolonged time was not possible due to the 
limitations in the extent of animal starvation. This protocol 
was approved by the Institutional Bioethics Committee on 
Animal Care and Experimentation at UFRJ.
Data analysis
Data analysis of insulin release in vitro and insulin 
effects over plasma glycemia was performed to obtain 
the rates by non-linear least squares fitting, using double 
exponential equation as follow: 
Ct = C0 + A1*exp(-k1*t) + A2*exp(-k2*t) Eq. 3
where Ct and C0 are the concentration of insulin or glucose 
at time t and zero, respectively; A and k are the event 
amplitude (concentration changes) and kinetic rates for 
phases 1 and 2, respectively. 
Statistical analysis
Statistical analysis was performed with the t-test. 
The significance of the differences in the pharmacological 
evaluation was calculated and values of p<0.05 were 
considered to be significant. The analyses were performed 
using the SigmaStat as implemented in SigmaPlot 11 
(Systat Software Inc).
RESULTS AND DISCUSSION
Characterization of the microparticles
We have prepared insulin-loaded microparticles 
using PCL and a simple w/o/w emulsification system. 
Our preparation yielded microparticles with average size 
of 9.8+0.6 mm, as evaluated by dynamic light scattering 
measurements (Figure 1). 
Optical microscopy imaging shows uniform, 
individualized spherical microparticles, with average 
sizes of 10.8 ± 4.6 mm (Figure 2), in agreement with 
DLS measurements. The particles have micrometric 
sizes, as demonstrated by the morphological evidences 
shown in the optical microscopy, because this data 
reveal compartmentalized microparticles. The insulin 
concentration in supernatant of the washing pool indicates 
efficiency of 64.5±6.8%. After freeze-dried samples 
L. H. Guerreiro, D. Silva, W. Girard-Dias, C. M. Mascarenhas, K. Miranda, M. Sola-Penna, E. Ricci Júnior, L. M. T. R. Lima
Braz. J. Pharm. Sci. 2017;53(2):e16039Page 4 / 8
were weighed and yield calculated for the process was 
88.4±4.2%.
In vitro release
Figure 3 shows the release kinetics in vitro for 
microencapsulated insulin formulation. In this result 
was possible to observe a burst effect with about 50% of 
insulin being released in the first 2 hours. The kinetics of 
in vitro release was shown biphasic with an initial burst 
effect in the first 2 h and a second phase of release, slower, 
approximately four days.
In vivo release
Were performed in vivo experiments using diabetic 
mice to evaluate the activity of insulin released over time. 
FIGURE 1 - Insulin-PCL particles size distribution. Particles 
were evaluated by DLS after dispersion in water. Mean particle 
diameter = 9.8 + 0.57 mm. Details in the Material and Methods 
section.
FIGURE 2 - Morphological characterization of insulin-loaded 
PCL microparticles. Optical microscopy (A, B and C). Scanning 
Electron Microscopy (D). Details in the Material and Methods 
section.
FIGURE 3 - Kinetics of human insulin release from PCL microparticles. A) Cumulative release in a linear time scale. Inset: detail 
view of kinetics at initial range. Solid lines correspond to best fitting using Equation 1. Results are depicted in Table I and II. B) 
Higuchi plot. Solid lines are solely to depict human insulin releasing phases. Data represents measurements in triplicate from 
kinetics performed with three microparticles batches. 
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Figure 4 shows that the formulation was able to reduce 
blood glucose levels of mice for 24 hours significantly 
different from that observed in the group of mice that 
received the commercial formulation of insulin R.
The development of formulations with insulin 
sustained release systems have been previously reported in 
the literature (Liu et al., 2007a, 2007b; Damgé et al., 2009; 
Han et al., 2009; Huynh et al., 2009; Kim et al., 2009; 
Klingler, Müller, Steckel, 2009; Ungaro et al., 2009). 
Almost recent studies use nanoparticles to increase the 
insulin effect. However, it was reported the nanoparticles 
may move from injection sites to the blood vessels 
leading to the capture of these by the liver and spleen and 
consequent loss of action (De Jong, Borm, 2008). Despite 
of all efforts, only a few systems for insulin pulmonary 
delivery reached the market, and one of these was removed 
after showed some side effects such as the formation of 
amyloid deposits in the lungs of patients (Lasagna-Reeves 
et al., 2010). The encapsulation efficiency of 64.5% is 
lower than the expected for the method of double-emulsion 
and solvent extraction using emulsion type w/o/w since 
other authors using a similar methodology obtained 
higher efficiency (Damgé, Maincent, Ubrich, 2007; Peng 
et al., 2012). However, the encapsulation efficiency 
per se is not an exclusion criterion in the development 
pipeline, once assured proper pharmacological profile and 
maintenance of physical-chemical stability of the peptide 
in the formulation. In preliminary studies we tried to use 
dialyzed insulin, but the formulations without excipients 
(metacreol, glycerol etc.) did not show satisfactory data 
(data not shown) indicating that our method, to keep these 
excipients, was able to better preserve this hormone.
Regarding the release profile in vitro was observed 
that the preparation have a release kinetic over three days, 
and the first day of a release of most of the material. The 
kinetics of release stresses of the first 2 hours was also 
observed in experiments using diabetic mice, and the 
hypoglycemic effect of the formulation was more than 24 
hours of experiment. Interestingly, despite having a release 
kinetics in vitro faster than those described by other authors 
working with similar formulations developed here, our in 
vivo release data shows a long-lasting action, suggesting a 
more effective stabilization. We believe that this stability 
is due in part because of the use of preformulated regular-
acting insulin from commercial source (insulin and 
adjuvants) to prepare the microparticles, since experiments 
using non-formulated insulin (without excipients) did 
not result in satisfactory encapsulation efficiency as well 
as in an erratic release profiles (data not shown). These 
data demonstrate that the encapsulation efficiency and 
quality of the resulting product for protein products in a 
biologically active form is dependent of the formulation 
process, including stabilization of the proteic active 
pharmaceutical ingredient. In fact, glycerol and metacresol 
are important excipients for the stability of commercial 
insulin formulations.
Glycerol is commonly used as an osmotic agent, 
but this adjuvant also can prevent the formation of 
high-molecular-weight protein and aggregates in the 
TABLE I - Kinetic parameters from the in vitro release of human 
insulin from the PCL microparticles. Parameters were obtained 
from data in Figure 3
MP: insulin
Rate constant k1 0.76 + 0.39 h-1
Rate constant k2 0.023 + 0.009 h-1
Amplitude A1 44.9 + 9.9 %
Amplitude A2 55.6 + 9.8 %
TABLE II - Kinetic parameters from the pharmacological 
evaluation of the glycemic effect of MP-insulin. Parameters 
were obtained from data in Figure 3
MP: insulin Soluble insulin
Rate constant k1 2.58 h-1 2.59 h-1
Rate constant k2 0.047 h-1 0.18 h-1
FIGURE 4 - Pharmacological evaluation of MP-insulin 
in diabetic mices. Streptozotocin-induced mices were 
administrated s.c. with regular human insulin solution (closed 
symbols; n=5) or insulin-loaded PCL microparticles (open 
symbols, n=5) and the glucose level was evaluated. Symbols 
represent mean ± SD. Inset: glycemia change at initial time 
range. * p<0.05 (t-test). Lines are non-linear regression with 
Eq. 1. Details in the Material and Methods section.
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compositions with insulin (Brange, Langkjaer, 1992). 
Phenol derivatives are used because of their antimicrobial 
effects as preservatives, but they are capable of reducing 
deamidation processes, which are the main route of 
degradation of insulins during storage (Whittingham et 
al., 1998). In additional, phenolic derivates can stabilize 
interactions between monomers and insulin dimers and 
hexameric conformation (Crommelin, Sindelar, Meibohm, 
2008). In this work we have not investigated the effects 
of the excipients alone since both are important for the 
stability of the compositions because they act in different 
ways, but further studies may be carried out in order to 
evaluate the stability of the insulins in polymer matrices 
in the presence of pharmaceutical adjuvants.
Another important finding in our study is the 
reduction in blood glucose in animals treated in the 
first points of the test. Thus, although high dose of 10 
IU versus 5 IU in control group, the microencapsulated 
formulation was able to prevent episodes of hypoglycemia 
in diabetic mice, a major side effect of commercial 
insulin formulations. Another important application of 
this system might be the prevention of amyloid insulin 
formation, since studies reporting insulin aggregates at the 
application site are frequent (Swift et al., 2002; Nagase, 
2009; Lasagna-Reeves et al., 2010). In contrast, polymer 
particles similar to those developed in this work have 
been used to inhibit markedly amyloidogenic proteins 
(Cabaleiro-Lago et al., 2010; Guerreiro et al., 2012).
CONCLUSION
Despite all efforts for developing intelligent drug 
delivery systems, the characteristics of complex peptides, 
like insulin, added to the specific needs for diabetes 
treatments make this a challenge that seems to have a 
distant end. Our work has shown a simple and scalable 
way to produce longer lasting insulin formulation with no 
hypoglycemic effect in the tested dose, which can improve 
the quality of the therapeutic intervention.
ABBREVIATIONS
PCL, poli-ε-caprolactone; MP, microparticles; 
w/o/w, water-in-oil-in-water emulsion; s.c., subcutaneous; 
STZ, streptozotocin; PVA, poly(vinil alcohol).
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